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A B S T R A C T
Aims: Ablation therapies are an innovative nephron-sparing alternative to radical nephrectomy for early stage
renal cancers, although determination of treatment success is challenging. We aimed to undertake a systematic
review of the literature to determine whether assessment of tumour perfusion may improve response assessment
or alter clinical management when compared to standard imaging.
Material and Methods: Two radiologists performed independent primary literature searches for perfusion ima-
ging in response assessment following ablative therapies (radiofrequency ablation and cryotherapy) focused on
renal tumours.
Results: 5 of 795 articles were eligible, totaling 110 patients. The study designs were heterogeneous with dif-
ferent imaging techniques, perfusion calculations, reference standard and follow-up periods. All studies found
lower perfusion following treatment, with a return of ‘high grade’ perfusion in the 7/110 patients with residual
or recurrent tumour. One study found perfusion curves were diﬀerent between successfully ablated regions and
residual tumour.
Conclusions: Studies were limited by small sample size and heterogeneous methodology. No studies have in-
vestigated the impact of perfusion imaging on management. This review highlights the current lack of evidence
for perfusion imaging in response assessment following renal ablation, however it suggests that there may be a
future role. Further prospective research is required to address this.
1. Introduction
In 2014, there were 12,523 new cases of renal cancer in the UK [1],
a number increased by 78% since the 1990s [1]. This can be partly
attributed to the increased use of cross-sectional imaging and the con-
sequent incidental ﬁnding of small, localised renal masses. As incidental
small renal masses have been shown to be generally of lower grade and
associated with longer disease-free survival than their symptomatic
counterparts [2], nephron-sparing treatments have become preferable
to conserve renal function. The surgical gold-standard is now con-
sidered to be partial nephrectomy (PN) [3].
An alternative to PN is ablative therapy either using high (radio-
frequency ablation, RFA; microwave ablation) or low temperatures
(cryotherapy). These techniques are particularly suited to patients with
co-morbidities leading to high surgical or anaesthetic risks, poor renal
function or a solitary kidney. Comparing percutaneous RFA to PN of
small renal masses, RFA has been shown to be associated with less
blood loss, smaller post-procedure drop in renal function and shorter
length of hospital stay [4–6]. Medium term outcomes are also com-
parable with no statistical diﬀerence in 5 year tumour-related survival
or local recurrence [5–8].
The challenge with ablative therapies is determining whether a
treatment is successful or not early in the course of treatment. Unlike
surgery where pathological assessment of resection margins is possible,
determination of complete ablation is more challenging. Early detection
of persistent or recurrent tumour will change future management,
particularly as the evidence for repeated, invasive surveillance biopsy is
inconclusive [9]. Current practice is for initial cross-sectional imaging
to be performed typically within 3 months post-procedure, and 3–6
monthly thereafter, the timing varying depending on institutional
practice. Ablation is deemed successful if CT shows a hypoattenuating
ablation zone with absence of contrast enhancement [10].
Features of persistent tumour that have been described include ir-
regular, nodular enhancement> 10 Hounsﬁeld Units (HU) within the
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ablated area [10]. Whilst contrast-enhancement gives an indication of
overall tissue contrast uptake (combination of both intra- and extra-
vascular compartments), it is aﬀected by contrast dose, administration
rate and cardiac output [11]. Whilst the same is true of quantitative
perfusion measurements the eﬀects of these variables can be controlled
and mitigated by longer imaging acquisition times and arterial input
measurements [12]. It remains unclear whether measuring perfusion is
advantageous over qualitative assessment and whether it has any im-
pact on subsequent management. Thus we performed a systematic re-
view of the available medical literature, focusing on whether perfusion
imaging has a role as a response biomarker in the assessment of abla-
tion therapies and whether perfusion imaging impacts on subsequent
management.
2. Materials and methods
2.1. Data sources and search strategy
We identiﬁed primary studies investigating perfusion imaging after
ablation of small renal masses from the PubMED database. We included
both cryoablation and radiofrequency ablation, with post-procedural
perfusion-CT or perfusion-MR or quantitative dual-energy CT.
The following combinations of search terms were applied to identify
relevant studies:
(“kidney” OR “renal”) AND (“tumour” OR “tumor” OR “carcinoma”
OR “lesion” OR “mass” OR “cancer”) AND (“RFA” OR “radiofrequency”
OR “radio frequency” OR “cryotherapy” OR “cryotherapy” OR “cryoa-
blation” OR “ablation” OR “ablative” OR “locoregional therapy”) AND
(“CT” OR “MRI” OR “perfusion” OR “dual energy” OR "dual-energy" OR
“response” OR “dynamic contrast enhanced CT “OR “dynamic contrast
enhanced MRI “OR “DCE-CT” OR “DCE-MRI” OR “quantitative" OR
“ASL” OR “arterial spin”).
Results were limited to human studies. No studies were excluded on
the basis of language. Relevant systematic reviews were read in full to
ensure appropriate studies had not been missed. The search was per-
formed independently by 2 radiologists with any disagreements re-
solved by consensus.
2.2. Selection criteria
Electronic abstracts of identiﬁed studies were read and the fol-
lowing exclusion criteria applied: case reports, narrative reviews, let-
ters/correspondence and conference abstracts were excluded as these
would not contribute suﬃcient unbiased data able to answer our re-
search question. An excluded study log recorded reasons for exclusions.
2.3. Data extraction
Data was extracted from the included full text articles and recorded
on a database (Excel, Microsoft, Redmond WA, USA). For each article
the publication details and primary characteristics (number of patients,
age, size and histology of lesions, ablative technique used, imaging
follow-up protocol, summary of ﬁndings) was recorded.
2.4. Meta-analysis
Whilst the intention was to perform a meta-analysis on the included
data, this was precluded as only a small number of studies have been
published with none sharing similar methodology.
3. Results
PRISMA (Preferred Reporting Items for Systematic reviews and
Meta-Analyses) guidelines for transparent reporting of systematic re-
views were followed (Fig. 1).
3.1. Eligible studies
The initial search performed on 12 February 2018 yielded 795 ar-
ticles. 724 articles were excluded following evaluation of abstracts. The
remaining 71 articles were retrieved in full text and eventually 5/71
(7.0%) studies were included in the systematic review [13–17]. Of
these, two studies investigated perfusion-MR following RFA [13,17]
and one study each investigated perfusion-MR following cryotherapy
[14], perfusion-CT following cryoablation [15], and dual-energy CT
after RFA [16].
3.2. Patient population
Characteristics for the included studies are listed in Table 1. 110
patients were included with an individual study range of 10 to 47 pa-
tients. The patient age and renal mass sizes were reported diﬀerently
between studies (range versus standard deviation). 4 studies were
limited to RCC; one study included RCC and angiomyolipomata. 4
studies were prospective; 1 was retrospective. 4 studies were European
in origin (Germany, Italy, 2 from UK); 1 was Korean. 7/110 patients
had residual disease or recurrence following ablation.
3.3. Reported results
With the limited published evidence and varied methodologies in
each of the ﬁve included papers, the reported results are summarised in
Table 2 and described below.
3.4. Changes in perfusion with therapy
Boss et al. [13] compared perfusion-MR (both arterial-spin labeling
and dynamic contrast enhanced MR) with T1W-gadolinium enhanced
MR. Studies were performed before, 1 day and 6 weeks after MR-guided
percutaneous RFA or RCCs. Prior to ablation, RCCs demonstrated
“heterogeneous perfusion with zones of cystic tissue necrosis com-
pletely lacking perfusion” with a mean tumour perfusion rate of
167 ± 81ml.100g−1. min−1. On the Day 1 imaging, the mean reduc-
tion was 73 ± 11%. In successful cases, the ablation zones demon-
strated further decrease in perfusion between Day 1 and 6 weeks. The
mean overall decrease from pre-treatment studies was 84 ± 14%. Wah
et al. [17] also performed DCE-MRI before and 1 month after percu-
taneous RFA of RCCs. They found perfusion decreased signiﬁcantly
within the ablation zone. Interestingly, the degree of pre-ablation per-
fusion was correlated with the time taken for complete ablation.
Chapman et al. [14] performed DCE-MRI before and 1 month after
cryoablation of RCCs in 18 patients. A surrogate measure of perfusion
was calculated and then comparisons were made between the signal of
the tumour, renal cortex and ablated area. Prior to treatment, mean
perfusion within the tumour was 98.0ml.100ml−1. min−1. On follow-
up imaging, mean perfusion ablation zone perfusion was
11.6 ml.100ml−1. min−1. This is a decrease of 88.2% (P=<0.001).
Only a single follow-up scan was performed on each patient.
Park et al. [16] used iodine-only images from dual-energy CT to
quantify iodine-uptake and therefore to infer perfusion following RFA.
No perfusion imaging was performed before treatment. Acquisitions
were taken in the pre-contrast, corticomedullary and late nephrogenic
phases. In successfully treated lesions, iodine uptake peaked in the late
nephrogenic phase (mean increase 12.1 ± 11.7 HU). Statistical ana-
lysis was not performed.
Squillaci et al. [15] performed qualitative Perfusion-CT 6–8 months
after laparoscopic cryoablation of small renal masses. No pre-therapy
perfusion-CT imaging was performed. Perfusion curves for successfully
treated ablation areas showed more gradual wash-in, lower peak am-
plitude, and slower washout compared with normal renal cortex.
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3.5. Detection of residual or recurrent disease
In the study by Boss et al. [13] in 2/10 patients there was recurrent
or residual disease identiﬁed using perfusion. In one patient, this
manifested as a fall in ablation zone perfusion on Day 1
(174ml.100g−1. min−1 to 66ml.100g−1. min−1) but no further de-
crease in perfusion after 6 weeks (64ml.100g−1. min−1). The ﬁndings
on perfusion corresponded to a suspicious area on T2W and Gadoli-
nium-enhanced T1W imaging, which was subsequently found to re-
present persistent RCC on biopsy. In a further patient, day 1 imaging
Fig. 1. PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) breakdown of systematic review search results.
Table 1
Characteristics of the included studies.
First author Single OR Multi-
centre
Accrual Histology Tumour size / cm Ablation procedure Imaging Timing of imaging
Year
Sample size
Boss Single Prospective RCC 1.6–3.9 MRI-guided RFA DCE and ASL
MRI
Before procedure
2006 Day 1
n=10 6 weeks
Squillaci Single Prospective RCC; angiomyolipoma 2.04 (1.5–2.9) Laparoscopic cryoablation Perfusion CT 6–8 months
2009
n=15
Chapman Single Prospective RCC 3.52 (SD ± 0.74) CT-guided percutaneous
cryoablation
DCE MRI Before procedure
2013 1 month
n=18
Park Single Retrospective RCC 2.0 (SD ± 0.9) 2 US-guided percutaneous RFA Dual-energy CT Mean 28 months (range
6–63 months)
2014 45 CT-guided percutaneous
cryoablation
n= 47
Wah Single Prospective RCC 2.5 (1.3–4.0) CT-guided percutaneous RFA DCE MRI Before procedure
2018 1 month
n=20
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conﬁrmed a 93% fall in perfusion (321ml.100g−1. min−1 to
25ml.100g−1. min−1), however at the next study, 12 months later,
high perfusion had returned (169ml.100g−1. min−1). No histological
conﬁrmation was obtained as the imaging was conclusive for relapse.
Chapman et al. [14] and Wah et al. [17] found no patients (0/18
and 0/20, respectively) with residual or recurrent tumour on the 1
month imaging.
Park et al. [16] detected tumour recurrence in 4/47 patients. In this
subgroup of patients, and unlike successfully ablated zones, iodine
uptake peaked in the corticomedullary phase. Iodine uptake was also
higher in areas of recurrent compared with controlled disease (mean
75.3 ± 40.9 HU v 7.4 ± 5.8 HU in the corticomedullary phase, and
52.1 ± 7.9 HU v 12.1 ± 11.7 HU in the late nephrogenic phase).
In the study by Squillaci et al. [15], 1/15 patients had residual tu-
mour on standard post-contrast imaging, as demonstrated by enhancing
nodularity at the tumour margin. On perfusion-CT, there was a char-
acteristic perfusion curve; fast and early wash-in, followed by a plateau,
and then progressive, uniform wash-out. Time-to-peak, wash-in rate,
peak contrast enhancement, blood volume, blood ﬂow, permeability,
and mean transit time were all diﬀerent between recurrent tumour and
successfully ablated areas. Formal statistical analysis was not per-
formed as there was only a single patient with recurrent tumour.
3.6. Eﬀect on clinical management
No study assessed impact on initial management thus current data is
insuﬃcient to draw any conclusions on the impact of perfusion imaging
on management.
4. Discussion
Our systematic review conﬁrms a paucity of research in to the role
of perfusion imaging as a response biomarker after ablation therapy in
SRTs. To date, there are only 5 small studies, 1 retrospective, using a
number of diﬀerent imaging techniques following diﬀerent ablation
therapies. Pre-procedure perfusion imaging was only obtained for 3 of
the studies. Perfusion in residual or recurrent disease has only been
studied in 7 patients.
Ablative therapies partly owe their success to the greater tumour
sensitivity to extremes of temperature compared to surrounding healthy
tissue [18]. The mechanisms of action of ablative therapies at a cellular
level have been previously described [19,20]. RFA uses a high-fre-
quency alternating current to generate frictional heat. Within the cen-
tral zone, immediately adjacent to the appliance tip, temperatures of
60-100°c cause direct and indirect cellular damage. The amount of
damage is dependent on the total amount of thermal energy, rate of
deposition, and thermal sensitivity of the tissues [18]. Above 60°c,
there is rapid coagulative necrosis. The mechanisms for the secondary
eﬀects of hyperthermia are less understood but include changes to a
combination of cell membrane permeability, mitochondrial function,
enzymatic function, and DNA replication [21,22,20,23]. In the transi-
tion zone, there is reversible, sub-lethal heating due to thermal con-
duction. Following treatment, immune response is seen within this re-
gion [19].
Cryoablation uses liqueﬁed gas that cools as it expands to cause
extremes of cold. The expansion within the probe creates a heat sink,
reducing temperatures to as low as -160°c. Cell death occurs when
tissue temperature reaches between −20°c and −40°c [24]. This area
of cooling needs to extend>1 cm beyond the tumour margin to cause
complete ablation [25,26]. Cryoablation has several mechanisms of
action. In areas of extreme cool, direct cell death is caused by cellular
dehydration. Secondary tissue damage occurs due to vascular injury
and ischaemia [27]. Cell apoptosis and a localised immune response are
seen at the peripheries of the central zone [28,29].
Following tumour ablation size-based response criteria may not
reﬂect the impact of therapy accurately as signiﬁcant change in size
may not occur. In the peri-procedural period following ablative
therapy, ablation zones have demonstrated varied size responses, even
including increased size [30]. Over time, there is involution in suc-
cessfully treated areas. Following RFA there is approximately a 50%
volume decrease after 2 years [31] and 75% decrease following
cryoablation [32].
In the absence of surgery and with the lack of pathological con-
ﬁrmation of complete tumour destruction, the ability to identify in-
complete ablation/recurrence early would allow further treatment at an
earlier time-point. In addition, current post-procedure imaging can be
Table 2
Results of the included studies.
First author Changes in perfusion of ablation zone
with successful therapy
No. of unsuccessful
ablations
Detection of residual or recurrent disease Eﬀect on clinical
management
Year
Sample size
Boss 73 ± 11% decrease in perfusion on Day
1; 84 ± 14% overall decrease by 6
Weeks.
2 / 10 Case 1 – 62% fall in perfusion on Day 1 but no further fall at 6 Weeks.
Findings correspond to suspicious area on conventional MRI and
subsequently biopsy-proven; Case 2 – 93% fall on Day 1; return to
53% of original perfusion at 12 months.
Not investigated
2006
n=10
Squillaci More gradual wash-in, lower peak
amplitude, slower wash-out than normal
renal cortex
1 / 15 Rapid early wash-in; plateau phase, and slow homogeneous wash-out
compared with normal renal cortex
Not investigated
2009
n=15
Chapman mean 88.2% decrease in perfusion at 1
Month
0 / 18 N/A Not investigated
2013
n=18
Park Peak contrast enhancement in late
nephrogenic phase; Mean enhancement
12.1 ± 11.7 HU
4 / 47 Peak contrast enhancement in cortico-medullary phase; Mean
enhancement 75.3 ± 40.9 HU
Not investigated
2014
n=47
Wah Mean 96% decrease in tumour perfusion
following RFA
0 / 20 patients N/A Not investigated
2018 (0 / 21 lesions)
n= 20
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inconclusive with a decision made to oﬀer further ablation; a robust
biomarker would be able to reassure that there is no recurrence without
the need for invasive biopsy or undergoing unnecessary re-treatment.
Current clinical practice is for pre- and post-contrast CT (or MR imaging
where there is renal impairment). Particularly in the peri-procedural
period, determination of successful tumour ablation can be challenging
with standard imaging and biopsy due to high false-positive and false-
negative rates [33–36]. The limitations of qualitative assessment are
well known. Contrast enhanced ultrasound has been suggested as an
alternative to cross-sectional imaging although not all tumours are
visible on B-mode ultrasound. In addition, the degree of enhancement is
subjective [37]. Assessing perfusion quantitatively, rather than en-
hancement, is more robust taking into account diﬀerences in contrast
agent administration, dose and cardiac output. As ablative therapy is
increasingly utilised as a management option [38], it is essential that
robust imaging biomarkers can be used to determine the success of
treatment.
Our systematic review indicates that more evidence is still required,
ideally through prospective studies. Studies have shown that success-
fully treated regions demonstrated reduced perfusion following therapy
and sustained reduction in perfusion after 6–19 months, akin to ob-
servations in a case series investigating renal cell carcinoma perfusion-
CT following anti-angiogenesis therapy [39], but there is still limited
data on the perfusion characteristics of residual or recurrent tumour.
Residual disease or local recurrence has been reported in 5.6% and
4.2% of cases, respectively, following RFA treatment of T1a renal tu-
mours [40]. It is important that future studies are powered to draw ﬁrm
conclusions with respect to perfusion characteristics in residual or re-
current tumour. In our review of the literature no recurrences were
detected just by perfusion imaging; the areas of abnormal perfusion
corresponded to expected morphological appearances. Demonstrating
any additional value over currently accepted contrast-enhanced CT or
MRI is needed for it to be accepted as standard care.
In conclusion to date there is only limited evidence for perfusion
imaging as a response assessment following ablative therapies. Further
adequately powered prospective research is needed to determine
whether there is an impact on clinical management for perfusion ima-
ging to become part of standard of care.
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